清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Abstract 3708: OMX-0407, a highly potent SIK3 inhibitor, sensitizes tumor cells to cell death and eradicates tumors in combination with PD-1 inhibition

作者
Christina Hartl,Ilona-Petra Maser,Tillmann Michels,Ronny Milde,Vanessa Klein,Philipp Beckhove,Nisit Khandelwal,Hannes Loferer,Stefan Bissinger
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:82 (12_Supplement): 3708-3708 被引量:4
标识
DOI:10.1158/1538-7445.am2022-3708
摘要

Abstract Post-translational modifications of DNA and histones can improve the intrinsic antitumor capacity of the immune system. Using the iOTarg screening platform, salt-inducible kinase 3 (SIK3) was identified as a novel epigenetic modulator in cancer therapy. SIK3, a serine/threonine kinase of the AMP-activated protein kinase family, is known for regulating the NF-κB driven gene landscape through phosphorylation of class IIa histone deacetylases (HDACs) and CREB-regulated transcriptional coactivators causing the tumor to evade death receptor-mediated killing. Moreover, salt inducible kinases were recently described to regulate cell cycle checkpoints and thereby promote cancer cell proliferation. We demonstrate that SIK3 knockdown abates downstream pro-survival signaling and induces cell death in a distinct panel of tumor cell lines. OMX-0407, an orally available, single-digit nanomolar inhibitor of SIK3 was shown to effectively reduce TNF-induced HDAC4 phosphorylation and downstream NF-κB activity in a dose-dependent manner, thereby enhancing apoptosis in murine and human tumor cell lines. OMX-0407 dose-dependent suppression of intratumoral NF-κB activity was shown in vivo in an MC38 NF-κB-luc reporter cell line. Using OMX-0407 monotherapy, this translated to significant tumor growth inhibition as well as prolonged survival in the highly immune infiltrated syngeneic murine colorectal carcinoma model MC38. Besides its direct inhibitory effects on cancer cells, OMX-0407 repolarizes the tumor microenvironment (TME) by strongly decreasing regulatory T cells (T-regs) and M2-polarized macrophages in the tumor bed, while not affecting the peripheral T cell compartment. Thus, exposure to OMX-0407 leads to a distinct pro-inflammatory TME, characterized by an expansion of activated cytotoxic T lymphocytes (CTL) and an increased CTL-to-T-reg ratio. Using an immune-excluded tumor phenotype as seen in the breast cancer mouse model EMT6, we demonstrated that OMX-0407 and anti-PD-1 act synergistically by combining the sensitization towards cell death with a reduction in immunosuppressive TME and an increase in cytotoxic T cell activity, despite having only minimal anti-tumor efficacy as monotherapy. Thereby, partial or complete tumor remission in 60% of the animals and extension of overall survival were achieved. In summary, OMX-0407, a first-in-class oral SIK3 inhibitor, demonstrates potent monotherapy efficacy in a pro-inflammatory tumor setting by reshaping the immune compartment and accelerating tumor cell death. The ability of OMX-0407 to remodel an immunosuppressed TME in a generally cold tumor setting, harbors great clinical potential for OMX-0407 combination therapy with anti-PD-1/PD-L1 immune checkpoint blockade, specifically in patients with high unmet medical need who are resistant to current immune checkpoint inhibitor monotherapy. Citation Format: Christina Hartl, Ilona-Petra Maser, Tillmann Michels, Ronny Milde, Vanessa Klein, Philipp Beckhove, Nisit Khandelwal, Hannes Loferer, Stefan Bissinger. OMX-0407, a highly potent SIK3 inhibitor, sensitizes tumor cells to cell death and eradicates tumors in combination with PD-1 inhibition [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 3708.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
标致的大船完成签到,获得积分10
1秒前
null的应助被科研通管家采纳,获得10
8秒前
null的应助被科研通管家采纳,获得10
8秒前
null的应助被科研通管家采纳,获得10
8秒前
n01W97的应助被科研通管家采纳,获得20
8秒前
罗密欧与傅里叶完成签到,获得积分10
10秒前
谦让的鹤轩完成签到,获得积分10
18秒前
戴肉肉完成签到 ,获得积分10
37秒前
善良的梦曼完成签到,获得积分10
37秒前
CodeCraft的应助被dianeil采纳,获得10
46秒前
59秒前
跳跃的冰安完成签到,获得积分10
1分钟前
dianeil发布了新的文献求助10
1分钟前
热心剑成完成签到,获得积分10
1分钟前
曾经的冰安完成签到,获得积分10
1分钟前
null的应助被科研通管家采纳,获得10
2分钟前
rarity完成签到 ,获得积分10
2分钟前
积极的向彤完成签到,获得积分10
2分钟前
完美觅山完成签到,获得积分10
2分钟前
梅梅美美完成签到 ,获得积分10
2分钟前
清爽的口红完成签到,获得积分10
2分钟前
认真的狗发布了新的文献求助20
3分钟前
虚幻唯雪完成签到,获得积分10
3分钟前
我是老大的应助被LeoAllen849采纳,获得40
3分钟前
nk完成签到 ,获得积分10
3分钟前
3分钟前
剁辣椒蒸鱼头完成签到 ,获得积分10
3分钟前
冷酷紫烟完成签到,获得积分10
4分钟前
null的应助被科研通管家采纳,获得10
4分钟前
null的应助被科研通管家采纳,获得10
4分钟前
null的应助被科研通管家采纳,获得10
4分钟前
null的应助被科研通管家采纳,获得10
4分钟前
科研通AI65的应助被海宁采纳,获得10
4分钟前
4分钟前
怕孤独的梦寒完成签到,获得积分10
4分钟前
风中黎昕完成签到 ,获得积分10
4分钟前
海宁发布了新的文献求助10
4分钟前
合适乐巧完成签到 ,获得积分10
4分钟前
shoemaker完成签到,获得积分10
4分钟前
夏纪完成签到 ,获得积分10
4分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185392
求助须知:如何正确求助?哪些是违规求助? 9574120
关于积分的说明 21834329
捐赠科研通 7782811
什么是DOI,文献DOI怎么找? 3434552
关于科研通互助平台的介绍 2558842
邀请新用户注册赠送积分活动 2481272